With Big Pharma on Campus, Who Will Look After the Public Interest?

Alison Bass

First posted 8/3/11 on Alison Bass

Medicare and social services for vulnerable Americans are not the only programs on the chopping block with Washington’s deal to raise the debt ceiling and cut trillions of dollars in government spending. Looming ahead may be deep cuts in funding for medical and science research, and that raises the specter of growing collaboration between academic centers and industry, including pharmaceutical and medical device companies.

Even before the debt deal was reached, partnerships between Big Pharma and universities have been on the rise, according to an article in the current issue of Chronicle of Higher Education. The article, Big Pharma Finds a Home on Campus, details this growing collaboration and the “many new ethical and practice questions” it raises, including the increasing potential for conflicts of interest.

Continue reading “With Big Pharma on Campus, Who Will Look After the Public Interest?”